To analyze the composition and diversity of gut microbiota in patients with advanced or metastatic NSCLC, and to explore the relationship between gut microbiota and response to anti-PD-1/PD-L1 therapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.